In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Trevena (TRVN – Research Report), with a price target of $2.00. The company’s shares opened today at $1.05.
Butler covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and Esperion. According to TipRanks, Butler has an average return of -5.5% and a 42.37% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trevena with a $5.50 average price target.
See today’s best-performing stocks on TipRanks >>
TRVN market cap is currently $11.21M and has a P/E ratio of -0.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Read More on TRVN:
